Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01802411 · ClinicalTrials.gov registry record · Phase 3
Intercostal Nerve Block With Liposome Bupivacaine in Subjects Undergoing Posterolateral Thoracotomy
A Phase 3 study, sponsored by Pacira Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 191
- Enrollment target
NCT01802411: Completed Phase 3 study, sponsored by Pacira Pharmaceuticals.
NCT01802411 is a Phase 3 study that has completed, run by Pacira Pharmaceuticals. The registered enrollment target is 191 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01802411, a Phase 3 study, has completed, sponsored by Pacira Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 191 participants
- Enrollment target
Study Summary
The purpose of the study is to examine the safety and efficacy of liposome bupivacaine for intercostal nerve block in subjects undergoing posterolateral thoracotomy.
Primary Outcome
AUC of pain intensity scores at rest through 72 hours postsurgery. Participants assumed a resting position that did not exacerbate his or her postsurgical pain. Pain intensity scores were measured at baseline and 1, 2, 4, 8, 12, 24, 36, 48, 60, and 72 hours postsurgery, at first request for rescue pain medication, and on day 12 using the numeric rating scale at rest (NRS-R; 0=no pain and 10=worst possible pain).
Interventions
- DRUG Placebo
- DRUG EXPAREL 266 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 191 participants |
| Start Date | 2012-12 |
| Est. Completion | 2013-06 |
| Phase | Phase 3 |
What the finished NCT01802411 record still lists
NCT01802411 is an interventional study that assigns participants to a tested intervention. The registered 191 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (75% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01802411 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01802411 about?
NCT01802411 is a clinical study titled "Intercostal Nerve Block With Liposome Bupivacaine in Subjects Undergoing Posterolateral Thoracotomy". The purpose of the study is to examine the safety and efficacy of liposome bupivacaine for intercostal nerve block in subjects undergoing posterolateral thoracotomy.
What is the current status of trial NCT01802411?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 191 participants. The study started on 2012-12. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01802411?
The interventions under investigation include: Placebo (DRUG), EXPAREL 266 mg (DRUG).
Who is sponsoring clinical trial NCT01802411?
This trial is sponsored by Pacira Pharmaceuticals, which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01802411's enrollment target sits among peer trials
191 1402nd of 2000 higher than 599 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04621435 · 191 participants · Phase 1
Imaging of Solid Tumors Using FAP-2286
- NCT06810544 · 191 participants · Phase 1
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- NCT01492972 · 192 participants · Phase 3
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
- NCT01973881 · 192 participants
Quantitative MRI for Myelofibrosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia